Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii

Tianshui Niu¹, Qixia Luo¹, Yaqing Li², Yanzi Zhou¹, Wei Yu³ and Yonghong Xiao¹*

Abstract

**Background:** We retrospectively analyzed the effect of tigecycline and cefoperazone/sulbactam therapies on the prognosis of patients with carbapenem-resistant Acinetobacter baumannii bloodstream infection (CRAB-BSI).

**Methods:** CRAB-BSI patients receiving tigecycline therapy or cefoperazone/sulbactam therapy between January 2012 and December 2017 was enrolled, and strict exclusion criteria were followed. The 28-day mortality of patients was analyzed. The impact of cefoperazone/sulbactam therapy on prognosis was evaluated using Cox multivariate regression analysis. The 28-day mortality of patients receiving cefoperazone/sulbactam monotherapy and cefoperazone/sulbactam-based combination therapy was also compared.

**Results:** Three hundred forty eight patients with CRAB-BSI were enrolled in the study. Two hundred ten patients were included after applying the exclusion criteria. Of these, 135 patients received tigecycline therapy and 75 patients received cefoperazone/sulbactam therapy. The 28-day mortality of patients in the latter group was significantly lower than that of the tigecycline group [29.3% vs. 51.9%; \( P = 0.001 \)]. Cox multivariate regression analysis revealed that cefoperazone/sulbactam therapy exerted a protective effect on the prognosis of patients [hazard ratio 0.566, 95% confidence interval (0.342–0.940); \( P = 0.028 \)]. Kaplan-Meier survival curve analysis indicated that the 28-day mortality of patients receiving cefoperazone/sulbactam therapy was lower than that of patients receiving cefoperazone/sulbactam monotherapy, but the difference was not significant (22.2% vs. 40%; \( P = 0.074 \)). However, the mortality of patients receiving cefoperazone/sulbactam with imipenem/cilastatin was significantly lower than that of patients receiving cefoperazone/sulbactam monotherapy (\( P = 0.048 \)).

**Conclusions:** Patients treated with cefoperazone/sulbactam therapy had a better clinical outcome. The mortality of patients receiving cefoperazone/sulbactam with imipenem/cilastatin seems to be the lowest.

**Keywords:** Acinetobacter baumannii, Carbapenem resistance, Tigecycline, Cefoperazone/sulbactam

Background

Acinetobacter baumannii (AB) is one of the most important pathogens associated with hospital-acquired infections worldwide. It causes a wide range of infections, such as respiratory tract infection, blood infection, abdominal infections, urinary tract infections, traumatic infection, central nervous system infection, skin infections, which seriously threaten the health of patients [1, 2]. Because AB is highly resistant to many antibiotics and disinfectants, it is difficult to eliminate, and as such, it often becomes established in the hospital environment [3]. Carbapenem antibiotics are the first-line drugs for treating AB infections [4]. However, because of their widespread use, AB resistance to carbapenem antibiotics has rapidly increased, especially among strains isolated from the intensive care unit [5]. In the United States, the incidence of carbapenem-resistant AB (CRAB) increased from 20.6% in 2002 to 49.2% in
standards [14]. Cefoperazone-sulbactam susceptibility was determined according to the CLSI standards [14]. BSI was assessed by following the criteria proposed by the US Centers for Disease Control and Prevention. Patients were included if they had at least one AB-positive blood culture and symptomatic disease (fever [>38 °C or <36 °C], chills, hypotension, or other symptoms); if patients had more than one episode of AB-BSI, only data from the first episode were included. Tigecycline therapy was defined as tigecycline monotherapy or tigecycline with other antibiotics (including cefoperazone/sulbactam), with tigecycline doses of at least 50 mg every 12 h (q12h) for more than 48 h [17]. Cefoperazone/sulbactam therapy was defined as cefoperazone/sulbactam monotherapy or cefoperazone/sulbactam with other antibiotics (without tigecycline), of which the dose of cefoperazone/sulbactam (cefoperazone: sulbactam, 2:1) was 1 g q6h or q8h, or 2 g q6h or q8h for more than 48 h.

The exclusion criteria were as follows: patients with CRAB who died within 48 h or patients administered antibiotics for less than 48 h; patients for whom clinically critical data were missing; and patients receiving treatment regimens that included neither tigecycline therapy nor cefoperazone/sulbactam therapy. Patients were included in the study in one of these arms regardless of the results of cefoperazone/sulbactam or tigecycline susceptibility testing. The prognosis of patients with CRAB was based on 28-day mortality.

Research
Two-step analysis was performed in the current study (Fig. 1). The effects of receiving tigecycline therapy and cefoperazone/sulbactam therapy on patients’ prognosis were first compared, and the patients were classed into low-risk (APACHE II < 20) and high-risk groups (APACHE II ≥ 20). The 28-day mortality of patients receiving tigecycline therapy and cefoperazone/sulbactam therapy in different risk groups was analyzed. Cox multivariate regression analysis was used to determine the impact of cefoperazone/sulbactam therapy on patient’s prognosis. Then, the 28-day mortality of patients receiving cefoperazone/sulbactam monotherapy and cefoperazone/sulbactam-based combination therapy was analyzed, and that of patients receiving cefoperazone/sulbactam monotherapy and cefoperazone/sulbactam-based combination therapy in different risk groups.

The following information was collected from the hospital information management system: demographic parameters, underlying disease, complications, vital signs, laboratory data on infection, acute physiology and chronic health assessment (APACHE II score), Pitt bacteremia score (PBS), clinical pulmonary infection score (CPIS), bacteriological tests, and use of antibiotics upon diagnosis of BSI.

Methods
Research design and patient selection
This study was conducted at the First Affiliated Hospital, College of Medicine, Zhejiang University, after receiving approval from the research ethics committee (Reference Number: 2017–699). We were granted ethical approval for a waiver of informed consent and accessed the medical records of the patients considered for inclusion. Patients with CRAB were enrolled in the study from January 2012 to December 2017. Carbapenem resistance was defined as a minimum inhibitory concentration (MIC) of ≥8 μg/ml for imipenem and meropenem, according to the breakpoints of the Clinical and Laboratory Standards Institute (CLSI) standards [14]. Cefoperazone-sulbactam susceptibility was based on the breakpoints for ampicillin-sulbactam (MIC of 16/8 μg/ml) [15]. Tigecycline susceptibility was determined using the US Food and Drug Administration breakpoints [16]. Susceptibility to other drugs was determined according
Statistical analysis
Statistical analysis was performed using SPSS22.0. Categorical variables were analyzed using the Chi-square or Fisher’s exact test, and continuous variables were analyzed using t-test and Wilcoxon rank-sum test. Cox regression analysis for multivariate analysis was used after evaluating the proportional hazard assumptions. Variables demonstrating a difference with a $P$-value of $< 0.1$ were included in the Cox regression analysis. Results from the Cox regression analysis were analysed and interpreted using a $P$-value of $< 0.05$ to indicate a statistically significant difference. Kaplan-Meier analysis was used to evaluate the survival curves of patients receiving different treatments. For the analyses, $P < 0.05$ was considered to indicate statistically significant difference.

Results
Demographic parameters and drug susceptibility testing
348 patients with CRAB infection were enrolled in the current study. After applying the exclusion criteria, 210 (60.3%) patients were included in the study. Of these, 135 patients (64.3%) received tigecycline therapy and 75 patients (35.7%) received cefoperazone/sulbactam-based therapy. The characteristics of patients receiving tigecycline therapy and cefoperazone/sulbactam therapy are compared in Table 1. The median age of patients receiving tigecycline therapy was 62 years (21–95 years), while the median age of patients receiving cefoperazone/sulbactam therapy was 60 years (3–85 years). In the two groups, approximately 70% of patients were male, and more than 70% of patients had been admitted to the intensive care unit during hospitalization. The median APACHE II score was higher in the tigecycline therapy group than in the cefoperazone/sulbactam therapy group [20 (9–33) vs. 18 (7–31)], but the difference was not significant. The median CPIS score was higher in the tigecycline therapy group than in the cefoperazone/sulbactam therapy group [7 (2–12) vs. 6 (2–10)]. Among 210 patients, 119 patients were secondary to lower respiratory tract infection, 35 patients were catheter-related infection and 26 patients were abdominal infection (Additional file 1: Table S1). The common underlying diseases in the two groups were hypertension, hepatitis B/cirrhosis. The common complications during hospitalization were pulmonary infection, septic shock, and respiratory failure.

Drug sensitivity testing revealed that over 90% of AB isolated from patients were resistant to cefepime, ceftazidime, imipenem, meropenem, and ampicillin/sulbactam; 88.8% of AB isolates from the tigecycline therapy group and 72.7% of AB isolates from the cefoperazone/sulbactam therapy group were resistant to cefoperazone/sulbactam. The resistance of AB isolates to tigecycline was not as pronounced, with 14.7% of isolates from the tigecycline therapy group and 14.3% of isolates from the cefoperazone/sulbactam therapy group resistant to that antibiotic (Additional file 1: Table S2).

Comparison of the 28-day mortality among different therapy groups
One hundred and thirty-five patients received tigecycline therapy, of which 70 patients (51.9%) died within 28 days (Table 1); and 75 patients received sulbactam therapy, of which 31 patients (41.3%) died within 28 days (Table 1). Further, the Kaplan-Meier survival curve revealed a significant reduction in the 28-day mortality ($P = 0.002$) in patients receiving cefoperazone/sulbactam compared with those receiving tigecycline (Fig. 2a). Patients receiving tigecycline were much more likely to have had septic...
shock \((P = 0.000)\) and multi-organ failure \((P = 0.017)\) (Table 1), this was consistent with the conclusion that patients receiving tigecycline have a higher mortality.

The patients were classed into low-risk and high-risk groups according to the APACHE II score \(< 20\) vs. \(\geq 20\). In the low-risk group, 66 patients (48.9%) received tigecycline therapy, with the 28-day mortality of 30.3% (20/66); while 48 patients (64.0%) received cefoperazone/sulbactam therapy, with the 28-day mortality of 18.8% (9/48) (Table 1). In the high-risk group, 69 patients (51.1%) received tigecycline therapy, with the 28-day mortality of 72.5% (50/69); and 27 patients (36.0%) received cefoperazone/sulbactam therapy, with the 28-day mortality of 48.1% (13/27) (Table 1). The Kaplan-Meier survival curve analysis revealed that in the high-risk group, the 28-day mortality of patients receiving cefoperazone/sulbactam therapy was significantly lower \((P = 0.042)\) than that of patients receiving tigecycline therapy (Fig. 2b, Fig. 2c).

**Cefoperazone/sulbactam therapy is a protective factor for patient prognosis**

A multivariate Cox logistic regression model was constructed. Univariate analysis indicated the following the \(P < 0.1\) variables: APACHE II score \(\geq 20\), CPIS > 7, cefoperazone/sulbactam therapy, hypertension, multiple organ failure (MOF), and stroke. Multivariate Cox regression analysis revealed that the APACHE II score of \(\geq 20\) during hospitalization [hazard ratio (HR) = 2.530, 95% confidence interval (CI) (1.571–4.075); \(P = 0.000\], CPIS > 7 [HR = 2.277, 95% CI (1.424–3.640); \(P = 0.001\)], and MOF [HR = 2.268, 95% CI (1.283–4.007); \(P = 0.005\)] were significantly associated with the 28-day mortality of patients. The cefoperazone/sulbactam therapy [HR =

| Note: Data are expressed as number (%) unless otherwise stated. Abbreviations: CRAB-BSI Acinetobacter baumannii bloodstream infection, PBS Pitt Bacteraemia Score, CPIS Clinical Pulmonary Infection Score APACHE II score, acute physiology and chronic health evaluation II, ICU intensive care unit; MOF, multiple organ failure |  |

---

**Table 1** Characteristics of CRAB-BSI patients with Tigecycline therapy and Cefoperazone/Sulbactam therapy

| Characteristic | Tigecycline therapy (n = 135) | Cefoperazone/Sulbactam therapy (n = 75) | \(P\) value |
|---------------|-------------------------------|----------------------------------------|-------------|
| Age (years)   | 62 (21–95)                    | 60 (3–85)                              | 0.086       |
| Male sex      | 94 (69.6%)                    | 55 (73.3%)                             | 0.571       |
| ICU admission | 101 (74.8%)                   | 55 (73.3%)                             | 0.814       |
| APACHE II score | 20 (9–33)                   | 18 (7–31)                              | 0.063       |
| APACHE II score < 20 | 66 (48.9%)               | 48 (64%)                              | 0.035       |
| APACHE II score \(\geq 20\) | 69 (51.1%)               | 27 (36%)                              | 0.035       |
| PBS           | 3 (0–7)                       | 3 (0–8)                                | 0.098       |
| CPIS          | 7 (2–12)                      | 6 (2–10)                               | 0.006       |
| 28 day mortality | 70 (51.9%)                  | 22 (29.3%)                             | 0.001       |
| APACHE II score < 20 | 30.3% (20/66)             | 18.8% (9/48)                           | 0.118       |
| APACHE II score \(\geq 20\) | 72.5% (50/69)              | 48.1% (13/27)                          | 0.023       |
| Underlying disease |                             |                                        |             |
| hypertension  | 58 (43.0%)                    | 23 (30.7%)                             | 0.053       |
| hepatitis/cirrhosis | 24 (17.8%)              | 19 (25.3%)                             | 0.131       |
| diabetes      | 22 (16.3%)                    | 12 (16.0%)                             | 0.560       |
| renal insufficiency | 23 (17.0%)                 | 11 (14.7%)                             | 0.406       |
| coronary      | 17 (12.6%)                    | 9 (12%)                                | 0.544       |
| respiratory   | 17 (12.6%)                    | 8 (10.7%)                              | 0.431       |
| tumor         | 9 (6.7%)                      | 5 (6.7%)                               | 0.622       |
| Comorbid conditions |                             |                                        |             |
| pulmonary infection | 51 (37.8%)                    | 24 (32.0%)                             | 0.247       |
| septic shock  | 41 (30.4%)                    | 5 (6.7%)                               | 0.000       |
| respiratory failure | 24 (17.8%)                 | 15 (20.0%)                             | 0.412       |
| MOF           | 16 (11.9%)                    | 2 (2.7%)                               | 0.017       |
| abdominal cavity infection | 12 (8.9%)           | 2 (2.7%)                               | 0.069       |
| stroke        | 3 (2.2%)                      | 4 (5.3%)                               | 0.208       |
| gastrointestinal bleeding | 5 (6.7%)            | 2 (2.7%)                               | 0.515       |
Fig. 2 (See legend on next page.)
0.566, 95% CI (0.342–0.940); $P = 0.028$ exerted a protective effect on the prognosis of patients (Table 2).

**The effect of cefoperazone/sulbactam monotherapy and combination therapy on patient prognosis**

Seventy-five patients received cefoperazone/sulbactam therapy, of which 30 patients (40%) received monotherapy and 45 patients (60%) received combination therapy (Table 3). The median APACHE II score of the cefoperazone/sulbactam monotherapy group was higher than that of the cefoperazone/sulbactam combination therapy group [19 (11–31) vs. 18 (12–31), respectively], but the difference was not significant. The 28-day mortality of patients receiving cefoperazone/sulbactam monotherapy was 40% (12/30), while that of patients received combination therapy was 22.2% (10/45) ($P = 0.082$) (Table 3). Further, the Kaplan-Meier survival curve revealed that the 28-day mortality in the cefoperazone/sulbactam combination therapy group was lower than that in the cefoperazone/sulbactam monotherapy group, but the difference was not statistically significant ($P = 0.074$) (Fig. 3a).

In the low-risk group, 18 patients received cefoperazone/sulbactam monotherapy, with the 28-day mortality of 27.8% (5/18); and 30 patients received cefoperazone/sulbactam combination therapy, with the 28-day mortality of 13.3% (4/30) (Table 3). In the high-risk group, 12 patients received cefoperazone/sulbactam monotherapy, with the 28-day mortality of 41.7% (5/12); and 30 patients received cefoperazone/sulbactam combination therapy, with the 28-day mortality of 26.7% (8/30) (Table 3).

**Table 2** Univariate and multivariate Cox regression analyses for mortality of patients with CRAB-BSI

|                      | Crude analysis | Adjusted analysis |
|----------------------|----------------|-------------------|
|                      | HR (95% CI)    | $p$ value         | HR (95% CI)     | $p$ value |
| $> 60$ years of age  | 1.382 (0.782–2.443) | 0.265             | -               | -         |
| Male sex             | 0.817 (0.512–1.303) | 0.395             | -               | -         |
| ICU admission        | 1.610 (0.852–3.041) | 0.143             | -               | -         |
| APACHE II score $\geq 20$ at infection | 2.346 (1.197–4.600) | 0.013             | 2.530 (1.571–4.075) | 0.000   |
| PBS > 3 at infection | 0.773 (0.418–1.429) | 0.411             | -               | -         |
| CPIS > 7 at infection | 2.107 (1.253–3.545) | 0.005             | 2.277 (1.424–3.640) | 0.001   |
| Sulbactam therapy    | 0.592 (0.344–1.020) | 0.059             | 0.566 (0.342–0.940) | 0.028   |
| Underlying disease   |                |                   |                |           |
| hypertension         | 1.562 (0.324–2.973) | 0.040             | 0.762 (0.496–1.171) | 0.214   |
| hepatitis/cirrhosis  | 1.004 (0.539–1.870) | 0.991             | -               | -         |
| diabetes             | 1.188 (0.640–2.204) | 0.586             | -               | -         |
| cardiac              | 1.188 (0.621–2.275) | 0.602             | -               | -         |
| respiratory          | 0.922 (0.481–1.764) | 0.805             | -               | -         |
| tumor                | 0.638 (0.224–1.817) | 0.638             | -               | -         |
| Comorbid conditions  |                |                   |                |           |
| pulmonary infection   | 0.825 (0.514–1.324) | 0.425             | -               | -         |
| septic shock         | 1.431 (0.859–2.384) | 0.169             | -               | -         |
| respiratory failure   | 1.035 (0.600–1.784) | 0.902             | -               | -         |
| MOF                  | 2.671 (1.399–5.103) | 0.003             | 2.268 (1.283–4.007) | 0.005   |
| abdominal cavity infection | 0.788 (0.331–1.877) | 0.590             | -               | -         |
| stroke               | 2.412 (0.875–6.648) | 0.089             | 1.789 (0.697–4.588) | 0.226   |
| gastrointestinal bleeding | 1.401 (0.537–3.653) | 0.491             | -               | -         |

Note: *$P < 0.1$ in the univariate analysis were entered into a multivariate analysis; $P \geq 0.1$ in the univariate analysis were not entered into a multivariate analysis*

Abbreviations: CRAB-BSI, Acinetobacter baumannii bloodstream infection; HR, hazard ratio; CI, confidence interval; PBS, Pitt Bacteraemia Score; CPIS, Clinical Pulmonary Infection Score; APACHE II score, acute physiology and chronic health evaluation II; ICU, intensive care unit; MOF, multiple organ failure.
with the 28-day mortality of 58.3% (7/12); and 15 patients received cefoperazone/sulbactam combination therapy, with the 28-day mortality of 40.0% (6/15) (Table 3). The Kaplan-Meier survival curve analysis revealed that the 28-day mortality of patients receiving cefoperazone/sulbactam therapy was lower than that of patients receiving cefoperazone/sulbactam monotherapy, but the difference was not significant (Fig. 3b, Fig. 3c).

In the cefoperazone/sulbactam combination therapy group, the common combination regimen was cefoperazone/sulbactam with imipenem/cilastatin (55.6%, 25/45), and cefoperazone/sulbactam with biapenem or meropenem (22.2%, 10/45). The 28-day mortality of patients receiving cefoperazone/sulbactam with imipenem/cilastatin was lower than that of patients receiving the cefoperazone/sulbactam monotherapy (16% vs. 40%, respectively) ($P = 0.048$) (Table 4).

**Discussion**

The mechanism of AB resistance is complex, which led to the increasing prevalence of MDR-AB [18, 19]. Drug-resistant AB infections are closely associated with increased patient mortality, the length of hospital stay, and hospitalization costs [20–22]. Currently, most AB isolates are resistant to first-line antibiotics and the effectiveness of tigecycline is controversial; the efficacy has been proven. Therefore, it is particularly urgent to explore the potential of the existing antibiotics and that of a combination therapy involving the existing antibiotics for AB treatment.

**Table 3** Characteristics of CRAB-BSI patients with Cefoperazone/Sulbactam monotherapy and Cefoperazone/Sulbactam based combination therapy

|                              | Cefoperazone/Sulbactam monotherapy (n = 30) | Cefoperazone/Sulbactam based combination therapy (n = 45) | P value |
|------------------------------|--------------------------------------------|---------------------------------------------------------|---------|
| Age (years)                  | 62 (21–95)                                 | 60 (3–85)                                               | 0.086   |
| Male sex                     | 20 (66.7%)                                 | 35 (77.8%)                                              | 0.211   |
| ICU admission                | 21 (70.0%)                                 | 34 (75.6%)                                              | 0.392   |
| APACHE II score              | 19 (11–31)                                 | 18 (12–31)                                              | 0.371   |
| APACHE II score < 20         | 18 (60.0%)                                 | 30 (66.7%)                                              |        |
| APACHE II score ≥ 20         | 12 (40.0%)                                 | 15 (33.3%)                                              |        |
| PBS                          | 3 (2–8)                                    | 3 (1–6)                                                 | 0.554   |
| CPIS                         | 6 (3–10)                                   | 6 (4–10)                                                | 0.969   |
| 28 day mortality             | 12 (40.0%)                                 | 10 (22.2%)                                              | 0.082   |
| APACHE II score < 20         | 27.8% (5/18)                               | 13.3% (4/30)                                            | 0.194   |
| APACHE II score ≥ 20         | 58.3% (7/12)                               | 40% (6/15)                                              | 0.288   |
| Underlying disease           |                                            |                                                         |         |
| hypertension                 | 13 (43.3%)                                 | 10 (22.2%)                                              | 0.046   |
| hepatitis/cirrhosis          | 8 (26.7%)                                  | 11 (24.4%)                                              | 0.518   |
| diabetes                     | 6 (20.0%)                                  | 6 (13.3%)                                               | 0.323   |
| renal insufficiency          | 4 (13.3%)                                  | 7 (15.6%)                                               | 0.533   |
| coronary                     | 2 (6.7%)                                   | 7 (15.6%)                                               | 0.216   |
| respiratory                  | 0 (0%)                                     | 8 (17.8%)                                               | 0.013   |
| tumor                        | 2 (6.7%)                                   | 3 (6.7%)                                                | 0.687   |
| Comorbid conditions          |                                            |                                                         |         |
| pulmonary infection          | 7 (23.3%)                                  | 17 (37.8%)                                              | 0.144   |
| septic shock                 | 2 (6.7%)                                   | 3 (6.7%)                                                | 0.687   |
| respiratory failure          | 8 (26.7%)                                  | 7 (15.5%)                                               | 0.188   |
| MOF                          | 1 (3.3%)                                   | 1 (2.2%)                                                | 0.643   |
| abdominal cavity infection   | 1 (3.3%)                                   | 1 (2.2%)                                                | 0.643   |
| stroke                       | 2 (6.7%)                                   | 2 (4.4%)                                                | 0.527   |
| gastrointestinal bleeding    | 1 (3.3%)                                   | 1 (2.2%)                                                | 0.643   |

Notes: Data are expressed as number (%) unless otherwise stated  
Abbreviations: CRAB-BSI Acinetobacter baumannii bloodstream infection, PBS Pitt Bacteraemia Score, CPIS Clinical Pulmonary Infection Score APACHE II score, acute physiology and chronic health evaluation II, ICU intensive care unit, MOF multiple organ failure
Fig. 3 (See legend on next page.)
Sulbactam is a synthetic, irreversibly competitive sublactam that has shown good clinical efficacy since its introduction [23]. Sulbactam is often combined with a β-lactam antibiotic, such as cefoperazone or ampicillin, to enhance its bactericidal action against MDR-AB. The cefoperazone/sulbactam combination is effective against AB infections [24]. Choi et al. reported that the 30-day mortality of patients with CRAB receiving cefoperazone/sulbactam [7/35 (20%)] was lower than that of patients with CRAB receiving imipenem/cilastatin [vs. 6/12 (50%), P = 0.065] [25]. Xia et al. reported that the 30-day survival rate of patients treated with cefoperazone/sulbactam or a cefoperazone/sulbactam combination regimen was significantly higher than that of patients who had not received cefoperazone/sulbactam (96.4% vs. 73.3%, respectively; P < 0.05), among patients with hospital-acquired pneumonia caused by CRAB [26].

However, AB resistance to sulbactam continues to increase with the extensive use of sulbactam. A survey in the United States demonstrated that the incidence of AB strains resistant to ampicillin/sulbactam rose from 35.2% in 2003–2005 to 41.2% in 2009–2012 [27]. AB resistance to cefoperazone/sulbactam in China increased from 25% in 2005 to 37.7% in 2014 [7]. In 2005, the US Food and Drug Administration approved tigecycline for treatment of complex abdominal infections, and complex skin and soft tissue infections, including complex appendicitis, burn infections, abdominal abscesses, deep soft tissue infections, and ulcer infections [28]. Because of its pronounced antibacterial activity and because a variety of bacteria are highly susceptible toward tigecycline, tigecycline is considered to be an off-label treatment for infections caused by MDR pathogens when the drug selection is limited.

Tigecycline is a commonly used drug for the treatment of pneumonia caused by AB resistant to carbapenem and other antibiotics, with a clinical curative effect of 60–88% [29–31]. However, tigecycline increases patient’s mortality. A meta-analysis of 14 randomized trials involving 7400 patients indicated no benefit of using tigecycline for treating severe infections compared with the use of standard antibiotics. In that study, the success rate of tigecycline treatment was lower than that of the control group [32]. Prasad et al. showed that tigecycline increases mortality (P = 0.01) and noncure rate (P = 0.01) [33]. The efficacy of sulbactam had also been compared with that of tigecycline. Ye et al. investigated pneumonia caused by MDR-AB, and reported no significant difference in the 30-day mortality between sulbactam group (17.9%) and tigecycline group (25.0%) patients (P = 0.259) [34]. Liang et al. reported that although tigecycline is often used to treat CRAB-induced pneumonia, tigecycline-based regimen is associated with increased mortality and failure rates. The mortality for a tigecycline-based regimen was 40.9% (65/159), while that of a sulbactam-based regimen was 8.3% (1/12) [35]. However, these studies focused on patients with pneumonia caused by CRAB, CRAB specimens mostly originated from the respiratory tract, and the sample size was small. Little is known about the clinical effects of different treatment regimens on CRAB-BSI.

In the current study, we compared the clinical effects of a tigecycline regimen with those of a cefoperazone/sulbactam regimen in detail. We found that 64.3% of patients followed the tigecycline regimen and only 35.7% patients followed the cefoperazone/sulbactam regimen, but the 28-day mortality in the latter group (35.7%) was lower than that in the former group (51.9%; P = 0.001). We also found that in the high-risk risk group (APACHE II score ≥ 20), 69 patients (51.1%) received tigecycline therapy, while 27 patients (36.0%) received cefoperazone/sulbactam therapy. However, the 28-day mortality in the sulbactam-treated group was lower than that in the tigecycline therapy group (48.1% vs. 72.5%, respectively; P = 0.042). The Cox multivariate regression

| Treatment (Number) | Treatment (Number) | 28 day mortality | p value |
|-------------------|-------------------|-----------------|---------|
| Sulbactam monotherapy (30) | Cefoperazone/Sulbactam (30) | 40% (12/30) | 0.065* |
| Sulbactam based combination therapy (45) | Cefoperazone/Sulbactam + Imipenem/cilastatin (25) | 16% (4/25) | 0.048* |
| | Cefoperazone/Sulbactam + Biapenem or Meropenem (10) | 33.3% (3/10) | 0.432 |
| | Cefoperazone/Sulbactam + Other antibiotic(10) | 33.3% (3/10) | 0.432 |

Note: * Asterisks indicate statistically significantly different from Cefoperazone/Sulbactam alone treatment (Chi-square test)
analysis indicated that the cefoperazone/sulbactam regimen exerted a protective effect on the patient's prognosis [HR = 0.566, 95% CI (0.342–0.940); P = 0.028]. Therefore, we believe that although the AB resistance rate to sulbactam is increasing, the sulbactam regimen continues to have a good therapeutic effect on CRAB-BSI. Although tigecycline shows pronounced antibacterial activity in vitro and is widely distributed in human tissues, its concentration in the serum is very low. The first dose of tigecycline is 100 mg, and it is followed by 50 mg every 12 h. The peak plasma concentration of tigecycline (C_max) was reported to be only 0.87 μg/ml, with the minimum concentration (C_min) only 0.13 μg/ml [36]. This impacts the antibacterial effect of tigecycline in the body. The antibacterial effect of tigecycline in vivo is not effective, and patients are more likely to develop septic shock leading to multiple organ failure and death, so there may be a higher mortality. We also found CPIS score was noted to be statistically significantly different on multivariate analysis, previously study indicated that patients with respiratory sources of infection may do poorly on tigecycline therapy as these infections are usually associated with a high inoculum of bacteria, which may have been a factor in the higher mortality in receiving tigecycline [37]. At the same time, using univariate analysis, we previously showed that tigecycline use is associated with carbenempen resistance in AB [38].

In the current study, patients receiving tigecycline with cefoperazone/sulbactam were classed as a tigecycline-treated group. Tigecycline is rarely used alone, and is often combined with cefoperazone/sulbactam or other antibiotics. We observed that the 28-day mortality in patients receiving tigecycline with cefoperazone/sulbactam was higher than that in patients receiving cefoperazone/sulbactam (50% vs. 29.3%, respectively; P = 0.06) (Additional file 1:Tables S3 and S4). Additionally, we also found that patients receiving combination therapy with tigecycline and an antibiotic other than cefoperazone/sulbactam or a carbapenem, had the highest mortality overall among patients receiving tigecycline-based combination therapy (53.3%) although the sample size was limited (Additional file 1:Table S3).

Currently, a combination therapy is used for treating MDR-AB [39], and the efficacy of sulbactam monotherapy and combination therapy has been reported. Kuo et al. compared treatment regimens for CRAB-BSI and found that the 30-day mortality of patients receiving ampicillin/sulbactam combined with carbapenem antibiotics was lower [8/26 (31%)] than that of patients receiving ampicillin/sulbactam monotherapy [2/5 (40%)], carbapenem antibiotics monotherapy [7/12 (58%)], and carbapenem antibiotics combined with amikacin [5/10 (50%)] [40]. Data presented in the current study suggest that the mortality of patients receiving cefoperazone/sulbactam combination therapy is lower than that of patients receiving cefoperazone/sulbactam monotherapy in the low-risk group (13.3% vs. 27.8%, respectively) and in the high-risk group (40.0% vs. 58.3%, respectively), but the differences were not significant. The sample sizes within the low and high risk groups in the cefoperazone/sulbactam group were small which may have resulted in non-statistically significant differences.

The 28-day mortality of patients treated with cefoperazone/sulbactam with imipenem/cilastatin was significantly lower than that of patients receiving cefoperazone/sulbactam monotherapy (P = 0.048). We believe that although AB is highly resistant to sulbactam and carbapenem antibiotics, receiving cefoperazone/sulbactam with imipenem/cilastatin has a good therapeutic effect as a routine regimen. Therefore, we recommend a combination therapy of cefoperazone / sulbactam and imipenem / cilastatin, even if the patient was infected with carbapenem or cefoperazone/sulbactam resistant Acinetobacter baumannii. This was mainly because the combination of imipenem / cilastatin and cefoperazone / sulbactam had a good synergistic effect, pharmacokinetic activity, clearance rate for severe bacterial infection [41–43].

The current study has some limitations. First, respiratory tract or other organ infections are common in patients with BSI. The current study focused on CRAB-BSI without a comprehensive assessment of the clinical impact of infections caused by other pathogens or BSI. Second, some patients enrolled in the current study had been transferred from other hospitals. AB-BSI may have occurred if antibiotics were used before the transfer; however, we were unable to collect detailed information on antibiotic use before the transfer, which may have impacted the outcome. Thirdly, this study is a retrospective study, we recommend that future research in the form of a clinical trial may be indicated to more firmly establish the role of cefoperazone/sulbactam in the treatment of CRAB-BSI, as research up to this point has largely been based on retrospective observational data.

Conclusions

In conclusion, a detailed comparison of the use of cefoperazone/sulbactam therapy and tigecycline therapy against CRAB revealed that mortality was lower in both high and low risk groups with the use of cefoperazone/sulbactam, but that the include population was small. Cox analysis indicated that the cefoperazone/sulbactam therapy exerts a protective effect on the patient's prognosis. We also found that the mortality of patients receiving cefoperazone/sulbactam with imipenem/cilastatin was lower than that of patients receiving cefoperazone/sulbactam monotherapy, and the difference was significant. These observations are of great significance and serve as a reference for clinical treatment.
Additional file

Additional file 1: Table S1. Source distribution of 210 strains of CRAB-BSL. Table S2. Drug resistance of A. baumannii. Table S3. 28 day mortality of Tigecycline monotherapy group and Tigecycline based combination therapy group. Table S4. 28 day mortality among CRAB-BSL patients with Tigecycline+Cefoperazone/Sulbactam and Sulbactam based combination therapy. (DOC 54 kb)

Abbreviations

APACHE II score: Acute physiology and chronic health evaluation II; CI: Confidence interval; CPRS: Clinical Pulmonary Infection Score; CRAB-BSL: Acinetobacter baumannii bloodstream infection; HR: Hazard ratio; ICU: Intensive care unit; MOF: Multiple organ failure; PBS: Pitt Bacteraemia Score

Acknowledgments

The authors acknowledge the role of all support staff and participating patients in the study.

Funding

This work was supported by grants from the National Key Research and Development Program of China (No. 2017YFC1200203) and the key research and development program of Zhejiang province (No. 2015C03032).

Availability of data and materials

Full datasets analysed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

Conceived and designed the experiments: TN, QL, and YX. Performed the experiments: TN, YL, and WY. Analyzed the data: TN, YZ and WY. Wrote the paper: TN and YX. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethics approval for this study was submitted and approved through Research Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1. Collaborative Initiative Center for Diagnosis and Treatment of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, college of Medicine, Zhejiang University, Hangzhou 310003, China. 2. Women’s Hospital School of Medicine Zhejiang University, Hangzhou 310003, China. 3. Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou Medical College, Hangzhou 310003, China.

Received: 6 December 2018 Accepted: 27 February 2019

Published online: 06 March 2019

References

1. Higgins PG, Dammhayn C, Hackel M, et al. Global spread of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother. 2010;65:233–8.
2. Boucher HW, Talbot GH, Bradley JS, et al. Rice LB, et al. bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:1–12.
3. Wu X, Chavez JD, Schweppe DK, et al. In vivo protein interaction network analysis reveals porin-localized antibiotic inactivation in Acinetobacter baumannii strain ABS057. Nat Commun. 2016;7:13414.
4. Maragakis LL, Perl TM. Acinetobacter baumanii: epidemiology, antimicrobial resistance, and treatment options. Clin Infect Dis. 2008;46:1254–63.
5. Garnacho Mu, Dimopoulos G, Poulaou G, et al. Task force on management and prevention of Acinetobacter baumannii infections in the ICU. Intensive Care Med. 2015;41:2057–75.
6. Nica RM, Miller LA, Amrine MH, et al. Acinetobacter baumannii 2002-2008: increase of carbapenem-associated multi-class resistance in the United States. Microb Drug Resist. 2010;16:209–15.
7. Hu FP, Zhu DM, Wang F, et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005–2014. Clin Microbiol Infect. 2016;22:519–514.
8. Guan X, He L, Hu B, et al. Laboratory diagnosis, clinical management and infection control of the infections caused by extensively drug-resistant gram-negative bacilli: a Chinese consensus statement. Clin Microbiol Infect. 2016;22:515–25.
9. Aggarwal R, Dewan A. Comparison of nephrotoxicity of Colistin with Polymyxin B administered in currently recommended doses: a prospective study. Ann Clin Microbiol Antimicrob. 2018;17:15.
10. US Food and Drug Administration. FDA drug safety communication: increased risk of death with Tyclo (tigecycline) compared to other antibiotics used to treat similar infections (2010). http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm. Accessed 18 Apr 2011.
11. Kadoryama K, Sakaeda T, Tamon A, et al. Adverse event profile of tigecycline: data mining of the public version of the U.S. Food and Drug Administration adverse event reporting system. Biol Pharm Bull. 2012;35:567–70.
12. Pelleg AY, Potortoki IA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Chemother. 2007;59:28–31.
13. Xiao T, Yu W, Niu T, et al. A retrospective, comparative analysis of risk factors and outcomes in carbapenem-susceptible and carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infections: tigecycline significantly decreases the mortality. Infect Drug Resist. 2018;11:595–606. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5926074/.
14. Wayne, P. 2018. Performance standards for antimicrobial susceptibility testing. 28th ed. CLSI supplement M100. Clinical and laboratory standards institute 38.
15. Liu X, Zheng H, Zhang W, et al. Tracking cefoperazone/sulbactam resistance development in vivo in a. Baumannii isolated from a patient with hospital-acquired pneumonia by whole-genome sequencing. Front Microbiol. 2016;19:1268.
16. Casal M, Rodriguez F, Johnson B, E, et al. influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J Antimicrob Chemother. 2009;64:69–72.
17. Xu L, Wang YL, Du S, et al. Efficacy and safety of Tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2016;61:323–30.
18. Falagas ME, Biziots IA. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007;29:630–6.
19. Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72:2372–87.
20. Nutman A, Glick R, Temkin E, et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect. 2014;20:1028–34.
21. Zhen X, Chen Y, Hu X, et al. The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China. Eur J Clin Microbiol Infect Dis. 2017;36:1989–94.
22. Lemos EV, de la Hoz FP, Alvis N, et al. Impact of carbapenem resistance, and treatment options. Clin Infect Dis. 2008;46:1254–63.
23. Casal M, Rodriguez F, Johnson B, E, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J Antimicrob Chemother. 2009;64:69–72.
24. Xu L, Wang YL, Du S, et al. Efficacy and safety of Tigecycline for patients with hospital-acquired pneumonia. Chemotherapy. 2016;61:323–30.
25. Falagas ME, Biziots IA. Pandrug-resistant gram-negative bacteria: the dawn of the post-antibiotic era? Int J Antimicrob Agents. 2007;29:630–6.
26. Nowak J, Zander E, Stefanik D, et al. High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial. J Antimicrob Chemother. 2017;72:2372–87.
27. Nutman A, Glick R, Temkin E, et al. A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia. Clin Microbiol Infect. 2014;20:1028–34.
28. Zhen X, Chen Y, Hu X, et al. The difference in medical costs between carbapenem-resistant Acinetobacter baumannii and non-resistant groups: a case study from a hospital in Zhejiang province, China. Eur J Clin Microbiol Infect Dis. 2017;36:1989–94.
29. Lemos EV, de la Hoz FP, Alvis N, et al. Impact of carbapenem resistance on clinical and economical outcomes among patients with Acinetobacter baumannii infection in Colombia. Clin Microbiol Infect. 2014;20:174–80.
30. Rafaﬁdis PI, Ioannidou EN, Falagas ME. Ampicillin/sulbactam: current status in severe bacterial infections. Drugs. 2007;67:1829–49.
31. Civeros JM, Reyes MJ, Pachon J, et al. Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clin Infect Dis. 1996;22:1026–32.
32. Choi JY, Kim CO, Park YS, et al. Comparison of efficacy of cefoperazone/sulbactam and imipenem/cilastatin for treatment of Acinetobacter baumannii bacteraemia. Yonsei Med J. 2006;47:63–9.
33. Xia JJ, Zhang DC, Xu YP, et al. A retrospective analysis of carbapenem-resistant Acinetobacter baumannii-mediated nosocomial pneumonia and the in vitro therapeutic benefit of cefoperazone/sulbactam. Int J Infect Dis. 2014;23:90–3.
27. Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med. 2016;11:21–6.
28. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43:518–24.
29. Curotto D, Fernández F, Vergara J, et al. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother. 2009;21:58–62.
30. Poullakou G, Kontopidou FV, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gramnegative pathogens. J Inf Secur. 2009;58:273–84.
31. Ye JJ, Lin HS, Kuo AJ, et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Inf Secur. 2011;63:351–61.
32. Tasina E, Hadich AB, Kokali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:833–44.
33. Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis. 2012;12(12):1699–709.
34. Ye JJ, Lin HS, Yeh CF, et al. Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. BMC Infect Dis. 2016;5:374.
35. Liang CA, Lin YC, Lu PL, et al. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect. 2018;24:908.e1–7.
36. Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012, Intensive Care Med. 2013;39:165–228.
37. Niu T, Xiao TT, Guo LH, et al. Retrospective comparative analysis of risk factors and outcomes in patients with carbapenem-resistant Acinetobacter baumannii bloodstream infections. Cefoperazone-sulbactam associated with resistance and tigecycline increased the mortality. Infection and Drug Resistance. 2018;11:2021–30.
38. Kiratisin P, Apisarnthanarak A, Kaewdaeng S. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates. Int J Antimicrob Agents. 2010;36:243–6.
39. Colardyn F, Faulkner KL. Intravenous meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem serious infection study group. J Antimicrob Chemother. 1996;38:253–37.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions